Net Profit Margin
since 2005
Calculation
Celgene Corp., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income (loss) attributable to Celgene1 | ÷ | Net product sales1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 26.51% | = | 100 | × | 4,046) | ÷ | 15,265) |
| Dec 31, 2017 | 22.66% | = | 100 | × | 2,940) | ÷ | 12,973) |
| Dec 31, 2016 | 17.87% | = | 100 | × | 1,999) | ÷ | 11,185) |
| Dec 31, 2015 | 17.49% | = | 100 | × | 1,602) | ÷ | 9,161) |
| Dec 31, 2014 | 26.44% | = | 100 | × | 2,000) | ÷ | 7,564) |
| Dec 31, 2013 | 22.79% | = | 100 | × | 1,450) | ÷ | 6,362) |
| Dec 31, 2012 | 27.04% | = | 100 | × | 1,456) | ÷ | 5,386) |
| Dec 31, 2011 | 28.05% | = | 100 | × | 1,318) | ÷ | 4,700) |
| Dec 31, 2010 | 25.10% | = | 100 | × | 881) | ÷ | 3,508) |
| Dec 31, 2009 | 30.25% | = | 100 | × | 777) | ÷ | 2,567) |
| Dec 31, 2008 | -71.74% | = | 100 | × | (1,534) | ÷ | 2,138) |
| Dec 31, 2007 | 17.41% | = | 100 | × | 226) | ÷ | 1,300) |
| Dec 31, 2006 | 8.50% | = | 100 | × | 69) | ÷ | 812) |
| Dec 31, 2005 | 14.28% | = | 100 | × | 64) | ÷ | 446) |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The financial trajectory between 2005 and 2018 is characterized by aggressive revenue expansion and a significant period of volatility in the late 2000s, followed by a sustained phase of high-margin profitability.
- Revenue Expansion
- Net product sales grew consistently throughout the analyzed period, rising from 446 million US dollars in 2005 to 15.265 billion US dollars by 2018. This represents a continuous and steep upward trend in market penetration and sales volume.
- Net Income Volatility and Recovery
- Net income experienced extreme fluctuations between 2005 and 2009. After modest gains in the first three years, a substantial net loss of 1.534 billion US dollars was recorded in 2008. This was followed by a sharp recovery in 2009, with net income returning to positive territory at 777 million US dollars, and continuing a general upward climb to peak at 4.046 billion US dollars in 2018.
- Net Profit Margin Analysis
- The net profit margin mirrored the volatility of net income, crashing to -71.74% in 2008 before rebounding to 30.25% in 2009. From 2010 onward, the margin stabilized, generally maintaining a range between 17% and 28%. The period ended with a margin of 26.51%, suggesting that the company successfully scaled its operations while maintaining strong efficiency in converting sales into profit.
AI Ask an analyst for more
Comparison to Competitors
Celgene Corp., net profit margin, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 26.51% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | 22.66% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 17.87% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 17.49% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 26.44% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 22.79% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 31, 2012 | 27.04% | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 28.05% | — | 24.08% | 17.46% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 25.10% | — | 31.56% | 15.92% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 30.25% | — | 32.09% | 56.42% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 31, 2008 | -71.74% | — | 28.57% | 25.47% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 31, 2007 | 17.41% | — | 22.12% | 11.19% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 8.50% | — | 21.29% | 8.85% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 14.28% | — | 30.56% | 15.62% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2018 | 26.51% | 19.82% |
| Dec 31, 2017 | 22.66% | 13.06% |
| Dec 31, 2016 | 17.87% | 20.78% |
| Dec 31, 2015 | 17.49% | 21.17% |
| Dec 31, 2014 | 26.44% | 21.24% |
| Dec 31, 2013 | 22.79% | 21.99% |
| Dec 31, 2012 | 27.04% | 18.53% |
| Dec 31, 2011 | 28.05% | 15.70% |
| Dec 31, 2010 | 25.10% | 15.16% |
| Dec 31, 2009 | 30.25% | 25.73% |
| Dec 31, 2008 | -71.74% | 18.17% |
| Dec 31, 2007 | 17.41% | 15.90% |
| Dec 31, 2006 | 8.50% | 22.24% |
| Dec 31, 2005 | 14.28% | 18.33% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., net profit margin, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Dec 31, 2018 | 26.51% | 12.61% |
| Dec 31, 2017 | 22.66% | 9.26% |
| Dec 31, 2016 | 17.87% | 12.80% |
| Dec 31, 2015 | 17.49% | 13.94% |
| Dec 31, 2014 | 26.44% | 14.40% |
| Dec 31, 2013 | 22.79% | 15.04% |
| Dec 31, 2012 | 27.04% | 13.92% |
| Dec 31, 2011 | 28.05% | 12.06% |
| Dec 31, 2010 | 25.10% | 11.90% |
| Dec 31, 2009 | 30.25% | 17.77% |
| Dec 31, 2008 | -71.74% | 13.00% |
| Dec 31, 2007 | 17.41% | 12.52% |
| Dec 31, 2006 | 8.50% | 15.30% |
| Dec 31, 2005 | 14.28% | 14.61% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).